MAPT and Alzheimer disease: Indeed, a biological definition of AD for research purposes, the ATN system based on Aβ, tau and neurodegenerative biomarkers, has been proposed by the National Institute on Ageing and Alzheimer's Association (NIA‐AA), which defines AD by the presence of pathological markers,129 and which has provoked debate into its use in practice.130